Kisspeptin dosage: what the research protocols actually used.

The short version

There is no standard kisspeptin dosage, because there is no approved kisspeptin product. Everything below is a research protocol — what scientists gave to defined groups of people, under supervision, to measure a hormonal response. It is not a guide for anyone to follow.

A few patterns stand out. The doses are tiny and route-dependent, given by vein, by injection under the skin, or more recently by nasal spray. The two main forms behave differently: kisspeptin-10 clears in about 4 minutes, while the longer kisspeptin-54 lasts about 27-28 minutes, so the longer form is used where a steadier signal is wanted. And the single most important dosing lesson is counterintuitive — giving more, or giving it constantly, does not produce a bigger or steadier effect. The receptor desensitizes within days (tachyphylaxis), so a well-spaced single dose often outperforms continuous exposure. Doses below are reported only as "studied at X in [population] by [route]."

Kisspeptin dosage: the doses studied in humans

Across the human literature, kisspeptin dosage has been explored by several routes, always in research settings:

• Intravenous infusion, early human studies: kisspeptin-54 at 4 pmol/kg/min over 90 minutes (Dhillo 2005).
• Intravenous bolus and infusion, healthy men: kisspeptin-10 at 0.3-1.0 µg/kg bolus, with continuous infusion at 1.5 µg/kg/h, producing dose-dependent LH and pulse-frequency increases ^[3].
• Intravenous infusion, hypothalamic amenorrhea: kisspeptin-54 at 0.01-1.00 nmol/kg/h, restoring LH pulsatility but desensitizing at the top dose ^[4].
• Subcutaneous bolus, IVF oocyte-maturation trigger: kisspeptin-54 at 3.2-12.8 nmol/kg, with the highest live-birth rate at about 9.6 nmol/kg and no OHSS at any dose ^[5].
• Intranasal: kisspeptin-54 at a 12.8 nmol/kg primary dose, the first demonstration of an effective needle-free route ^[6].

Each figure is a study protocol matched to a population and a route — not a personal dose. The peptide is investigational and not a supplement ^[7].

Kisspeptin half life

Kisspeptin half life differs sharply between the two main forms, and it shapes how each is used. Kisspeptin-10 has a functional half-life of roughly 4 minutes in humans — plasma peptidases clear it quickly, so its action is brief and best suited to short, sharp stimulation. Kisspeptin-54 lasts longer, about 27-28 minutes (27.6 ± 1.1 minutes reported by Dhillo 2005), because its larger size and greater resistance to endopeptidase cleavage slow its breakdown. That longer duration is why kisspeptin-54 is the form used as an IVF trigger ^[5] and in the amenorrhea infusion studies ^[4], where a more sustained signal is wanted. Neither figure implies a dosing schedule; they explain why the two isoforms are studied for different purposes.

Kisspeptin nasal spray

A kisspeptin nasal spray became a real research option in 2025, when intranasal kisspeptin-54 (12.8 nmol/kg) rapidly stimulated LH release in healthy men (+4.4 IU/L), healthy women (+1.4 IU/L) and women with hypothalamic amenorrhea (+4.4 IU/L) with no adverse events; the formulation was stable for up to 60 days at 4 °C ^[6]. The significance is the route, not a new dose — it shows the peptide can reach the bloodstream and switch on the reproductive axis without an injection, which matters for any future study population that would not tolerate repeated needles. It remains investigational; the result is a delivery proof-of-concept, not an approved product.

Why continuous dosing defeats itself: tachyphylaxis

The defining limitation of any kisspeptin dosing schedule is tachyphylaxis — a rapid fall in response with repeated or sustained exposure. Twice-daily subcutaneous kisspeptin-54 in women with hypothalamic amenorrhea drove a strong day-1 LH response (about 24 IU/L) that fell to about 2.5 IU/L by the 14th injection day ^[16]. High-dose continuous intravenous infusion likewise showed desensitization during the infusion itself ^[4]. The mechanism is receptor downregulation: hold the switch down and it stops responding. Because kisspeptin-10 clears fast, receptor sensitivity may be better preserved with well-spaced or pulsatile exposure than with continuous administration — which is precisely why the single-bolus IVF trigger works so cleanly while continuous protocols fade. None of this is a recommendation; it is the reason the literature treats dosing timing as more important than dosing amount.